As you might expect, the competition to win a share of the expanding GLP-1 market is fierce right now, with giants Novo Nordisk ( NVO +0.47%) and Eli Lilly ( LLY +4.57%) slugging it out, while Pfizer ...

A White House deal with Eli Lilly & Co. and Novo Nordisk to lower the prices of their popular obesity medicines, Zepbound and Wegovy, is a step toward making them more affordable and accessible ...

Emcure Pharma becomes the first Indian company to hold exclusive rights to distribute and commercialise Poviztra, a ...

Novo Nordisk India and Emcure Pharma have partnered to launch Poviztra (semaglutide 2.4 mg), a second brand of Wegovy®, in ...

Drugmaker Eli Lilly said it would soon start late-stage trials for eloralintide, a drug mimicking the pancreatic hormone amylin that slows digestion and reduces hunger.

Below, doctors explain everything you need to know about the phenomenon. It’s important to be clear upfront that “Ozempic ...

Medicare will cover GLP-1 weight loss drugs for specific patient groups, beginning in mid-2026, under a deal struck with drugmakers.

A man who fainted in the Oval Office last week was a patient of a weight-loss drug company, according to reports.

Weight-loss trends have been around for years, with the latest being GLP1 drugs like Ozempic or Wegovy. Meg Bowman, licensed nutritionist and trauma expert weighs in on what's causing these weight ...

There’s plenty to like about the lower direct-to-consumer prices the White House negotiated with Eli Lilly and Novo Nordisk. There are also caveats and some unanswered questions.

The deal involves Eli Lilly, which makes Zepbound and Mounjaro, and Novo Nordisk, the maker of Ozempic and Wegovy. The drugs, known as GLP-1 medications, now cost as much as $1350 a month. Under the ...

Oral GLP-1 weight loss pills could replace injections by March 2026 at $150 monthly, Medicare chief Dr. Mehmet Oz predicted in a FOX Business appearance.